Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy

Breast

Volumn 21, Issue 5, 2012, Pages 662-668

  Larsen, Mathilde S ^a,b   Bjerre, Karsten ^c   Lykkesfeldt, Anne E ^b   Giobbie Hurder, Anita ^d   Lænkholm, Anne Vibeke ^e,f   Henriksen, Katrine L ^b,g   Ejlertsen, Bent ^c   Rasmussen, Birgitte B ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c University of Copenhagen   (Denmark)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f SLAGELSE HOSPITAL   (Denmark)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Breast cancer; Endocrine resistance; ER positive; HER receptors; Phosphorylated HER

Indexed keywords

DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; LETROZOLE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE ACTIVATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL;

EID: 84865982782     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.07.005     Document Type: Article

References (42)

1. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
2. McDonnell D.P. The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. Clin Cancer Res 2005, 11:871s-877s.
3. Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. N Eng J Med 2003, 348:2431.
4. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7:505-516.
5. Zahnow C.A. ErbB receptors and their ligands in the breast. Expert Rev Mol Med 2006, 8:1-21.
6. Frogne T., Laenkholm A.V., Lyng M.B., Henriksen K.L., Lykkesfeldt A.E. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res 2009, 11:R11.
7. Frogne T., Benjaminsen R.V., Sonne-Hansen K., Sorensen B.S., Nexo E., Laenkholm A.-V., et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009, 114:263-275.
8. Nicholson R.I., Hutcheson I.R., Jones H.E., Hiscox S.E., Giles M., Taylor K.M., et al. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev Endocr Metab Disord 2007, 8:241-253.
9. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643.
10. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935.
11. Houston S.J., Plunkett T.A., Barnes D.M., Smith P., Rubens R.D., Miles D.W. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999, 79:1220-1226.
12. Newby J.C., Johnston S.R., Smith I.E., Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997, 3:1643-1651.
13. Nicholson R.I., Hutcheson I.R., Harper M.E., Knowlden J.M., Barrow D., McClelland R.A., et al. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci 2002, 963:104-115.
14. Rasmussen B.B., Regan M.M., Lykkesfeldt A.E., Dellórto P., Del Curto B., Henriksen K.L., et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008, 9:23-28.
15. Chan S.K., Hill M.E., Gullick W.J. The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 2006, 11:3-11.
16. Walker R.A., Bartlett J.M.S., Dowsett M., Ellis I.O., Hanby A.M., Jasani B., et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol 2008, 61:818-824.
17. Dowsett M., Allred C., Knox J., Quinn E., Salter J., Wale C., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008, 26:1059-1065.
18. Joensuu H., Isola J., Lundin M., Salminen T., Holli K., Kataja V., et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003, 9:923-930.
19. Sun J.M., Han W., Im S.A., Kim T.-Y., Park I.A., Noh D.-Y., et al. A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma. Cancer 2004, 101:2516-2522.
20. Dowsett M., Houghton J., Iden C., Salter J., Farndon J., A'Hern R., et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006, 17:818-826.
21. Wright C., Nicholson S., Angus B., Sainsbury J.R.C., Farndon J., Cairns J., et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992, 65:118-121.
22. Naidu R., Yadav M., Nair S., Kutty M.K. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998, 78:1385-1390.
23. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., Bartlett J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200:290-297.
24. Bieche I., Onody P., Tozlu S., Driouch K., Vidaud M., Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003, 106:758-765.
25. Koutras A.K., Kalogeras K.T., Dimopoulos, Wirtz R.M., Dafni U., Briasoulis E., et al. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer 2008, 99:1775-1785.
26. Lee Y., Cho S., Seo J.H., Shin B.K., Kim H.K., Kim I., et al. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast. Am J Clin Pathol 2007, 128:1041-1049.
27. Sassen A., Rochon J., Wild P., Hartmann A., Hofstaedter F., Schwarz S., et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008, 10:R2.
28. Tovey S., Dunne B., Witton C.J., Forsyth A., Cooke T.G., Bartlett J.M. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?. Clin Cancer Res 2005, 11:4835-4842.
29. Zhu Y., Sullivan L.L., Nair S.S., Williams C.C., Pandey A.K., Marrero L., et al. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res 2006, 66:7991-7998.
30. Pawlowski V., Revillion F., Hebbar M., Hornez L., Peyrat J.P. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000, 6:4217-4225.
31. Suo Z., Risberg B., Kalsson M.G., Willman K., Tierens A., Skovlund E., et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002, 196:17-25.
32. Naresh A., Thor A.D., Edgerton S.M., Torkko K.C., Kumar R., Jones F.E. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 2008, 68:6387.
33. Thor A.D., Liu S., Edgerton S., Moore D., Kasowitz K.M., Benz C.C., et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000, 18:3230-3239.
34. Cicenas J., Urban P., Kung W., Vuaroqueaux V., Labuhn M., Wight E., et al. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer 2006, 42:636-645.
35. Mouridsen H., Giobbie-Hurder A., Goldhirsch A., Thurlimann B., Paridaens R., Smith I., et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361:766-776.
36. Henriksen K.L., Rasmussen B.B., Lykkesfeldt A.E., Moller S., Ejlertsen B., Mouridsen H.T. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 2007, 60:397-404.
37. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847.
38. Pinhel I.F., MacNeill F.A., Hills M.J., Salter J., Detre S., A'Hern R., et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Can Res 2010, 12:R76.
39. http://www.nordicq.org.
40. Amin D.N., Campbell M.R., Moasser M.M. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 2010, 21:944-950.
41. Lee-Hoeflich S.T., Crocker L., Yao E., Phan T., Munroe X., Hoeflich K.P., et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68:5878-5887.
42. Liu B., Ordonez-Ercan D., Fan Z., Edgerton S.M., Yang X., Thor A.D. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007, 120:1874-1882.